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Background. Hormone replacement therapy (HRT) in the past has been used in one of five
women but not without significant short-term and long-term consequences.
Objective. The aim of the study is to assess the prescription of HRT in general practice to women
consulting with menopausal symptoms, before and after publication of the Women’s Health
Initiative (WHI) study (2002), the Million Women Study and the Lancet Editorial (2003), and to
correlate these with co-morbidity, co-medication and frequency of GP consultation.
Methods. The study was performed using data collected by a Dutch Continuous Morbidity Reg-
istration. We selected women who presented with menopausal symptoms for the first time dur-
ing the period 1999–2007 (n = 341). Women who were prescribed HRT between 2002 and 2007
were compared with women presenting with menopausal symptoms without HRT prescription
and women who did not consult for menopausal symptoms. Both control groups were matched
for age, socio-economic status and general practice.
Results. HRT prescription decreased considerably: from 37% in all women who present with
menopausal symptoms at the GP 2002 to 14% in 2003 and 4% in 2004. Women who consulted
for menopausal symptoms, irrespective of HRT prescription, presented with nervous functional
complaints more often, were prescribed more tranquillizers and visited the GP more frequently
than women who did not consult for menopausal symptoms.
Conclusions. These GPs were very quick to implement new recommendations on HRT prescrip-
tion. The decision to prescribe HRT was not correlated with specific emotional or psychiatric
problems of the menopausal women.
Keywords. General practice, hormone replacement therapy, menopausal symptoms.
Introduction
Hormone replacement therapy (HRT) has been used
in one of five women aged >50 years in the last
decade of the 20th century.1 The therapeutic goal of
HRT was defined as decreasing vasomotor symptoms
and preventing osteoporosis and cardiovascular dis-
eases.2 The Women’s Health Initiative (WHI) study
in 20023 and the Million Women Study (MWS) in
2003,4 accompanied by an editorial in The Lancet,5
launched a new debate on the side effects of HRT.
Both studies concluded that the use of HRT increases
the risk of breast cancer, cardiovascular diseases, cere-
brovascular accidents, dementia and venous thromboem-
bolic disorders. As a consequence, HRT prescription in
the USA decreased by 34%.6 Apparently, many patients
stopped using HRT or used HRT in lower doses. In The
Netherlands too, a dramatic change took place in the
prescription of HRT. The Dutch Association of General
Practitioners (Nederlands Huisarts Genootschap: NHG)
developed a guideline Menopause in 2001, which was
very reluctant in prescribing HRT. The editorial in The
Lancet, mentioned above, was in the summer of 2003 ac-
companied by much general media publicity in The
Netherlands. In 2006, the NHG College published a short
‘Point of view’ in addition to the existing guideline of
2001.
Menopausal symptoms may severely impede daily
life.7 About 70% of women experience symptoms, but
only a minority of these will visit their GP.8 In general,
only 10% of episodes of experienced ill health are pre-
sented to the GP, which includes menopausal symptoms.9
As a consequence, the use of HRT has been associated
by some GPs with inadequate coping strategies of men-
opausal women, who are not able to cope well with
symptoms relating to a ‘natural’ phase of transition.10
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It is important, therefore, to study the context of
women who consult for menopausal symptoms. Im-
proved understanding of co-morbidity can lead to a
better understanding of the context in which women
ask for help and why they were prescribed HRT. The
WHI and MWS studies were performed in the general
population and not in general practice among women
who consulted the GP for menopausal symptoms. They
also lack control groups. The Continuous Morbidity
Registration (CMR) Project at Radboud University Nij-
megen Medical Centre offers an ideal opportunity to in-
vestigate these questions. The CMR is a practice-based
long-standing database, recording all health problems
that patients present to their GPs.11 The CMR, there-
fore, gives us the opportunity to follow a cohort through
time and to study characteristics of menopausal women.
The aim of our study was to assess changes in HRT
prescription by GPs in women with menopausal com-
plaints before and after the publication of some leading
articles about HRT and to investigate the differences
in co-morbidity, co-medications and frequency of GP
consultation between women presenting with meno-
pausal symptoms who were prescribed HRT and those
who were not and those who did not present with
menopausal symptoms at all.
Methods
The morbidity and demographic data used in this his-
torical cohort study were obtained from the Nijmegen
Continuous Morbidity Registration Project. The meth-
odology of the CMR has been described in detail else-
where and can be summarized as follows. Since 1971,
this registration project has been ongoing in four gen-
eral practices (currently involving 10 GPs) in and
around Nijmegen, The Netherlands, meticulously re-
cording all morbidity and mortality data in the patient
population of these practices.
The recording is anchored in the Dutch health care
system, which is primary care based, with general
practice being the main provider of health care and
the gatekeeper of access to specialist medical care.
Every citizen is listed with a personal GP, usually over
a longer period of time. As a consequence, patients’
general practice records are the focal point of all
relevant medical information. The practice population
comprises 12 000 patients, with 25–27% women in the
age group 45–64 years old.12
The patient population is representative of the pop-
ulation of The Netherlands.11 The available socio-
demographic data for every patient include sex, age,
socio-economic status (SES) and marital status (single,
married/living together and widowed). SES is assigned
in line with Centraal Bureau Statistiek Statistics Neth-
erlands indicators, a composite scale of educational
and occupational level, categorized into low, middle
and high.13
Diagnostic coding in the CMR used to be based on
the classification that was available in 1971 (the Dutch
translation of the E-book), and, to ensure continuity,
this classification has been maintained but made com-
patible with the International Classification of Primary
Care (ICPC-2).14 The validity of the recorded diagno-
ses has been shown to be well above 80%, mainly due
to the regular monthly meetings of the registering GPs
to review and compare their classification.15
All newly diagnosed patients presenting with meno-
pausal symptoms between 1999 and 2007 were identi-
fied. Coding of menopausal symptoms is done by the
patient’s own GP at the time of first presentation
based on the diagnostic definition of menopausal
symptoms. Two cohorts were formed. The first cohort,
1999–2002, related to the years preceding publication
of the WHI study (2002), the MWS (2003) and The
Lancet editorial (2003); the second cohort, 2003–07,
related to the years after publication.
The following data were obtained from the comput-
erized database:
- background characteristics: age, general practice,
marital status and SES and
- co-morbidity at the time of presenting menopausal
symptoms: nervous functional complaints, psychiatric
disorders, chronic somatic diseases such as diabetes
mellitus, overweight (body mass index > 25), thyroid
disorders (hyper- and hypofunction), cardiovascular
diseases and hypertension. Hysterectomy was also
recorded.
In the CMR, nervous functional complaints are de-
fined as a special and separate category of emotional
disorders in general practice. Criteria for this diagnosis
are: (i) absence of organic lesions that could explain
complaints and (ii) positive findings of stress-related
disorders that would explain complaints.
For psychiatric disorders, we focused on the most
prevalent ones: depression and anxiety disorders. Car-
diovascular diseases included myocardial infarction,
angina pectoris, peripheral arterial disease, congestive
heart failure, atrial fibrillation, transient ischaemic
attack and cerebrovascular accident.
We derived the following data from patients’ Elec-
tronic Medical Records (EMRs):
- information about first-choice treatment and, if not
effective, treatment at the second consultation;
- prescription of analgesics, tranquillizers and anti-
depressants during the first year after diagnosis;- fre-
quency of GP consultation defined as number of face-
to-face contacts between patient and GP other than
for menopausal symptoms in the 2 years preceding
the first presentation of menopausal symptoms. We
divided the number of contacts into three categories:
none, 1–8 and >8 contacts (frequent attenders).
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Analysis of the EMR gave us the women with men-
opausal symptoms who were prescribed HRT in the
2003–06 period. These women, matched for age, SES
and general practice, were compared with a group
of women who visited their GP with menopausal
symptoms in the same period (coded as such in the
ICPC-2) but who did not receive HRT prescription.
Then, we compared all women who presented with
menopausal symptoms in the 2003–06 period (irre-
spective of HRT prescription) with a group of women
who had never presented with menopausal symptoms.
This group was also matched for age, SES and general
practice.
Data were analysed using the Statistical Package for
the Social Sciences (SPSS version 12.0.1). Statistical
analysis was performed using the chi-square test and
Fischer’s exact test. In our study, we defined results
with a P-value <0.05 as significant.
Results
A total of 341 patients visited their GP with meno-
pausal symptoms (Table 1). Women who presented
with symptoms had no children or one child signifi-
cantly more often than the general Dutch population.
There were no differences in terms of SES.
HRT prescription
Prescription of HRT as treatment of choice decreased
significantly after 2003: from 37% (n = 16) in 2002
to 4% (n = 1) in 2004, with a slight increase in 2006
(n = 5) (P = 0.001) (Fig. 1). None of those prescribed
HRT were given it at follow-up consultations neither
did they perceive depressants instead of HRT pre-
scription. Prescription of oral contraceptives to treat
menopausal symptoms also decreased (P = 0.01). In-
formation and guidance clearly replaced hormone
therapy as a first-choice approach: from 34% in 1999
to 60% in 2006 (P = 0.05). Information and guidance
increased throughout the study period, peaking when
HRT prescription is lowest in 2004. That year the
number of patients presenting with menopausal symp-
toms is also the least.
Women presenting with menopausal symptoms: HRT
users versus non-users
The HRT users (n = 33) did not differ from the non-
users in chronic somatic and psychiatric diseases, ner-
vous functional complaints, prescription of analgesics
or frequency of GP consultation (Table 2).
Women presenting with menopausal symptoms versus
women not presenting with menopausal symptoms
Women with menopausal symptoms presented more
often with nervous functional complaints (P = 0.03)
and received more tranquillizers than women who did
not present with menopausal symptoms to their GP
(Table 3) (P = 0.001). They also attended the GP
more frequently than women without menopausal
symptoms (P = 0.03).
The women who presented with menopausal symp-
toms did not receive significantly more antidepressants,
but the P-value (P = 0.05) was close to significance
(Table 3). No differences in chronic somatic or psychi-
atric diseases were found between the two groups.
Discussion
The publication of the studies about the side effects of
HRT had a tremendous impact on prescription behav-
iour in general practice, showing a significant policy
change from GPs prescribing HRT to their giving infor-
mation and guidance. This is in accordance with the rec-
ommendations we made in the editorial of The Lancet.5
Not prescribing HRT is not followed by an increase in
HRT prescriptions at follow-up consultations.
Remarkably, women presenting with menopausal
symptoms also had more nervous functional com-
plaints, had higher consultation rates and used more
tranquillizers, irrespective of HRT use. This may be
to control anxiety or insomnia due to night flushed or
is related to the functional nervous complaints. We
conclude that the most important difference in co-
morbidity and frequency of GP consultation between
menopausal women is not whether they received a pre-
scription of HRT or not, but rather whether they seek
TABLE 1 Characteristics of patients who present with menopausal
symptoms between 1999 and 2006 (n = 341)
Characteristic % (n)
Mean age at the moment of first presentation 49.4 years (SD 4.3)
Civil status
Married/co-habiting 74.8 (255)
Single 11.4 (39)
Widow 3.8 (13)
Divorced 9.4 (32)
Unknown 0.6 (2)
SES
High 17.0 (58)
Middle 35.8 (122)
Low 32.0 (109)
Unknown 15.2 (52)
Number of children
0 (14%a) 19.1 (65)
1 (14%a) 20.2 (69)
2 61.7 (107)
Co-morbidity
Overweight 15.8 (54)
Hypertension/CVD 11.4 (39)
Nervous functional complaints 29.6 (101)
Psychiatric problems 8.8 (30)
Hysterectomy 9.3 (32)
CVD, cardiovascular diseases.
aPercentage women in The Netherlands with none/one child.14
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help or not. Women not presenting with menopausal
symptoms to their GP either do not suffer from any
symptom or do not present to the health care system.
It is important to mention that our study shows that
women who were prescribed HRT should not be defined
as a specific group of women with emotional or psychiat-
ric problems. The HRT prescription is not correlated
with emotional or psychiatric characteristics of meno-
pausal women and has nothing to do with inadequate
coping strategies. It is possible that severity of hot
flushes played an important part in this decision and that
therapy has been prescribed on a personal needs basis.
Women who were prescribed HRT do not suffer
more frequently from chronic somatic and psychiatric
diseases. Our results are largely consistent with an
Australian study that revealed no differences between
users and non-users of HRT in chronic diseases such
as diabetes mellitus, asthma, arthritis, osteoporosis and
FIGURE 1 First-choice treatment of the GP in women with menopausal symptoms (n = 341)
TABLE 2 Co-morbidity, co-medication and number of consultation in
women with HRT prescription versus group with menopausal symp-
toms without HRT
HRT users
(n = 33),
n (%)
Control group
without HRT use
(n = 33), n (%)
P-value
Fischer’s
exact test
Chronic somatic diseases 11 (33.3%) 7 (21.2%) 0.408
Nervous functional
complaints
15 (45.5%) 9 (27.3%) 0.200
Psychiatric diseases 4 (12.1%) 1 (3.0%) 0.355
Hysterectomy 1 (3.0%) 4 (12.1%) 0.355
Analgesics 8 (24.2%) 9 (27.3%) 1.000
Antidepressants 7 (21.2%) 1 (3.0%) 0.054
Tranquillizers 10 (30.3%) 8 (24.2%) 0.783
Number of consultations
0 1 (3.0%) 2 (6.06%) 0.251
1–8 18 (54.5%) 21 (63.6%)
>8 14 (42.4%) 10 (30.3%)
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obesity.16 Nor did hormone therapy users in the Aus-
tralian study differ from non-users in quality of life.
A recent study re-emphasized the importance of
increasing awareness of the negative side effects of
HRT: 3 years after stopping HRT, there was still an
increased risk of fatal and non-fatal malignancies.17
HRT is also associated with an increased risk of stroke
and venous thromboembolism.18,19 The recent fall in
use of HRT in Australia was followed by a reduction
in breast cancer incidence, suggesting a causal rela-
tion.20 This is consistent with the evidence that HRT-
associated increased risk of breast cancer is reversible
after ceasing HRT use.
Our study has some limitations. Firstly, it is a retro-
spective study based on data from medical records.
GPs may have differed in when and how they classi-
fied complaints as menopausal symptoms and coded
them as such, even if GPs are well trained in coding
diseases and achieve high validity in their diagnoses.15
Secondly, the study is limited to four academic practi-
ces (with 10 GPs of the Department of General Prac-
tice), although the study population is representative
of the general Dutch population. There is also a possi-
bility that GP’s practising in an academic practice and
well schooled in providing the CMR data might be
more compliant with prescribing change than other
GP’s. Thirdly, there were only a small number of
women who were ultimately prescribed HRT.
A strength of our study is the long-term and precise
morbidity registration in the CMR practices, which
serves as a solid foundation for patient follow-up and
to follow a cohort through time. The number of pa-
tients (341) and the absence of dropouts and selection
bias also support the credibility of the findings. Lastly,
the database allowed us to compose two appropriate
control groups, within the cohort.
Conclusions
Following publication of leading articles about HRT
at the beginning of the 21st century, GPs’ HRT pre-
scription in four Dutch practices changed. This im-
plementation of evidence-based guidelines was rapid,
showing significant reduction of HRT prescriptions
to women with menopausal symptoms and significant
increase in advice and guidance since. We think that
the current prescription is more in line with an optimal
treatment of menopausal symptoms than in the past.
Women who present with menopausal symptoms to
their GP need special attention and care because of
the presence of nervous functional complaints, the in-
creased number of consultations and the use of tran-
quillizers. Hormone therapy is not recommended as
treatment of choice; instead, information and guidance
are prerequisites for therapy tailored to the individual.
The decision to prescribe HRT, however, is not corre-
lated with specific psychological or psychiatric charac-
teristics of menopausal women.
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